Clinical bottom line
The presence of comorbidities in older cancer patients significantly influences treatment decisions and outcomes. Clinicians must carefully evaluate comorbid conditions when formulating treatment plans, as they can impact the efficacy and tolerability of cancer therapies. Recent evidence suggests that tailored approaches considering comorbidities can improve patient outcomes and reduce adverse events.What the evidence shows
A growing body of literature highlights the impact of comorbidities on cancer treatment and outcomes in older adults. A systematic review by Extermann et al. (2018) emphasized that comorbidities are prevalent in older cancer patients and can complicate treatment decisions, often leading to under-treatment or inappropriate treatment choices (PMID: 29367697). The study found that patients with multiple comorbidities had a higher risk of treatment-related toxicity and poorer overall survival compared to those with fewer comorbidities.Furthermore, a recent cohort study by Galsky et al. (2020) investigated the effects of comorbidities on treatment outcomes in older patients with metastatic bladder cancer. The findings indicated that patients with higher comorbidity scores experienced worse overall survival and increased treatment-related complications (PMID: 31958653). This underscores the necessity for clinicians to assess comorbidity burden when considering aggressive treatment options.
Additionally, the American Society of Clinical Oncology (ASCO) guidelines recommend incorporating comorbidity assessments into treatment planning for older adults with cancer. The guidelines suggest using tools such as the Charlson Comorbidity Index or the Cumulative Illness Rating Scale to evaluate comorbidity burden and inform treatment decisions (PMID: 31958653).
Caveats and uncertainty
While the evidence supports the consideration of comorbidities in treatment decisions, there are limitations to the current studies. Many studies rely on retrospective data, which may introduce bias and limit the generalizability of findings. Additionally, the definitions and assessments of comorbidities can vary between studies, complicating comparisons and interpretations.Moreover, the impact of specific comorbidities on treatment outcomes may differ based on cancer type, stage, and treatment modality. As such, further research is needed to better understand the nuances of how individual comorbid conditions affect treatment efficacy and safety across diverse cancer populations.
How this may change practice
The recognition of comorbidities as a critical factor in treatment decision-making may lead to more personalized and effective care for older cancer patients. Clinicians may adopt a more holistic approach, integrating comprehensive geriatric assessments into routine oncology practice. This could facilitate discussions about treatment goals, preferences, and the potential risks and benefits of various therapeutic options.By acknowledging the role of comorbidities, clinicians can better tailor treatment plans, potentially improving patient outcomes and quality of life. Furthermore, this approach may help mitigate the risk of overtreatment or undertreatment, ensuring that older patients receive appropriate and effective cancer care.